{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Weekly+procrit+dosing&page=2", "query": { "intervention": "Weekly procrit dosing", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Weekly+procrit+dosing&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-23T11:14:21.907Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00436748", "title": "Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia", "Chronic Kidney Disease", "Kidney Disease" ], "interventions": [ { "name": "Darbepoetin Alfa", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 116, "start_date": "2008-09-16", "completion_date": "2014-03-03", "has_results": true, "last_update_posted_date": "2022-11-29", "last_synced_at": "2026-09-23T11:14:21.907Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00436748" }, { "nct_id": "NCT03169881", "title": "Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neurocognitive", "Neuroprotective", "Neonatal", "Neurodevelopmental Impairment" ], "interventions": [ { "name": "Darbepoetin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NICHD Neonatal Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Hour", "maximum_age": "24 Hours", "sex": "ALL", "summary": "1 Hour to 24 Hours" }, "enrollment_count": 650, "start_date": "2017-09-20", "completion_date": "2025-05-12", "has_results": true, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-09-23T11:14:21.907Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT03169881" }, { "nct_id": "NCT00313716", "title": "Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Anemia", "Traumatic Brain Injury" ], "interventions": [ { "name": "recombinant human erythropoietin, rhEpo", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Claudia Sue Robertson", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 200, "start_date": "2006-04", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2014-09-10", "last_synced_at": "2026-09-23T11:14:21.907Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00313716" }, { "nct_id": "NCT01467115", "title": "Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Radiotherapy", "type": "RADIATION" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Erythropoetin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG", "BIOLOGICAL" ], "sponsor": "Drexel University College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2010-03", "completion_date": "2014-10-07", "has_results": false, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-09-23T11:14:21.907Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01467115" }, { "nct_id": "NCT03400033", "title": "Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anaemia" ], "interventions": [ { "name": "Daprodustat tablets", "type": "DRUG" }, { "name": "Matching placebo tablets", "type": "DRUG" }, { "name": "Epoetin alfa vials", "type": "DRUG" }, { "name": "Saline vials or bags", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 407, "start_date": "2018-09-05", "completion_date": "2020-06-19", "has_results": true, "last_update_posted_date": "2021-07-12", "last_synced_at": "2026-09-23T11:14:21.907Z", "location_count": 23, "location_summary": "Mesa, Arizona • Fresno, California • Los Angeles, California + 19 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Paramount", "state": "California" }, { "city": "Middlebury", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03400033" }, { "nct_id": "NCT01876732", "title": "Impact of Vitamin B12 Replacement on Epogen Dosing and Improvement of Quality of Life in Hemodialysis Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Vitamin B12 Deficiency" ], "interventions": [ { "name": "Vitamin B12", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 132, "start_date": "2009-06", "completion_date": "2011-04", "has_results": true, "last_update_posted_date": "2014-09-08", "last_synced_at": "2026-09-23T11:14:21.907Z", "location_count": 1, "location_summary": "Staten Island, New York", "locations": [ { "city": "Staten Island", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01876732" }, { "nct_id": "NCT00440557", "title": "An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia" ], "interventions": [ { "name": "Epoetin alfa 3 times weekly /once weekly", "type": "DRUG" }, { "name": "Epoetin alfa once weekly", "type": "DRUG" }, { "name": "Epoetin alfa once every two weeks", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 375, "start_date": "2006-09", "completion_date": "2008-02", "has_results": true, "last_update_posted_date": "2014-05-07", "last_synced_at": "2026-09-23T11:14:21.907Z", "location_count": 61, "location_summary": "Glendale, Arizona • Tempe, Arizona • Chula Vista, California + 58 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00440557" }, { "nct_id": "NCT02052310", "title": "Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia in Incident Dialysis Patients" ], "interventions": [ { "name": "Roxadustat", "type": "DRUG" }, { "name": "Epoetin Alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyntra Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1043, "start_date": "2014-02-11", "completion_date": "2018-09-21", "has_results": true, "last_update_posted_date": "2021-10-01", "last_synced_at": "2026-09-23T11:14:21.907Z", "location_count": 30, "location_summary": "Chula Vista, California • La Mesa, California • San Diego, California + 25 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Coral Springs", "state": "Florida" }, { "city": "Lauderdale Lakes", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02052310" }, { "nct_id": "NCT01147666", "title": "Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "End Stage Renal Disease", "Anemia" ], "interventions": [ { "name": "Roxadustat", "type": "DRUG" }, { "name": "Epoetin Alfa", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Kyntra Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 161, "start_date": "2010-05-17", "completion_date": "2012-10-15", "has_results": true, "last_update_posted_date": "2022-01-11", "last_synced_at": "2026-09-23T11:14:21.907Z", "location_count": 25, "location_summary": "Tempe, Arizona • Pine Bluff, Arkansas • Azusa, California + 22 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Pine Bluff", "state": "Arkansas" }, { "city": "Azusa", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01147666" }, { "nct_id": "NCT01628107", "title": "A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Renal Failure Requiring Hemodialysis" ], "interventions": [ { "name": "Epoetin Hospira", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 406, "start_date": "2012-07-16", "completion_date": "2015-01-02", "has_results": true, "last_update_posted_date": "2018-07-19", "last_synced_at": "2026-09-23T11:14:21.907Z", "location_count": 108, "location_summary": "Azusa, California • Bellflower, California • Commerce, California + 57 more", "locations": [ { "city": "Azusa", "state": "California" }, { "city": "Bellflower", "state": "California" }, { "city": "Commerce", "state": "California" }, { "city": "Cudahy", "state": "California" }, { "city": "Encino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01628107" } ] }